KR102594083B1 - Mic 항체 및 결합제 및 이의 사용 방법 - Google Patents

Mic 항체 및 결합제 및 이의 사용 방법 Download PDF

Info

Publication number
KR102594083B1
KR102594083B1 KR1020227046132A KR20227046132A KR102594083B1 KR 102594083 B1 KR102594083 B1 KR 102594083B1 KR 1020227046132 A KR1020227046132 A KR 1020227046132A KR 20227046132 A KR20227046132 A KR 20227046132A KR 102594083 B1 KR102594083 B1 KR 102594083B1
Authority
KR
South Korea
Prior art keywords
cancer
ser
delete delete
thr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227046132A
Other languages
English (en)
Korean (ko)
Other versions
KR20230012072A (ko
Inventor
제니퍼 동란 우
Original Assignee
칸큐어 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칸큐어 엘엘씨 filed Critical 칸큐어 엘엘씨
Priority to KR1020237036123A priority Critical patent/KR20230152783A/ko
Publication of KR20230012072A publication Critical patent/KR20230012072A/ko
Application granted granted Critical
Publication of KR102594083B1 publication Critical patent/KR102594083B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227046132A 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법 Active KR102594083B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237036123A KR20230152783A (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063049012P 2020-07-07 2020-07-07
US63/049,012 2020-07-07
PCT/US2021/040445 WO2022010847A1 (en) 2020-07-07 2021-07-06 Mic antibodies and binding agents and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237036123A Division KR20230152783A (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20230012072A KR20230012072A (ko) 2023-01-25
KR102594083B1 true KR102594083B1 (ko) 2023-10-25

Family

ID=77127088

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227046132A Active KR102594083B1 (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법
KR1020237036123A Pending KR20230152783A (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237036123A Pending KR20230152783A (ko) 2020-07-07 2021-07-06 Mic 항체 및 결합제 및 이의 사용 방법

Country Status (9)

Country Link
US (2) US12139539B2 (enExample)
EP (1) EP4178678A1 (enExample)
JP (1) JP2023532852A (enExample)
KR (2) KR102594083B1 (enExample)
CN (1) CN116249716A (enExample)
AU (1) AU2021305084A1 (enExample)
CA (1) CA3184940A1 (enExample)
TW (1) TW202216776A (enExample)
WO (1) WO2022010847A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118414352A (zh) * 2021-10-27 2024-07-30 美国株式会社三养生物制药 具有变体fc结构域的抗-mic抗体
WO2023225626A2 (en) * 2022-05-20 2023-11-23 Adanate, Inc. Multi-targeting lilrb antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315287A1 (en) 2011-05-31 2012-12-13 University Of Washington Through Its Center For Commercialization Mic-binding antibodies and methods of use thereof
US20160368991A1 (en) * 2013-07-05 2016-12-22 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
WO2020086776A1 (en) * 2018-10-23 2020-04-30 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
JP2002517409A (ja) 1998-06-02 2002-06-18 デンドレオン コーポレイション 抗原提示細胞組成物の調製およびインビボ投与のための方法
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
KR100617337B1 (ko) 1998-12-23 2006-08-31 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
BR0014945A (pt) 1999-10-21 2004-08-31 Monsanto Co Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
AU1811801A (en) 1999-12-03 2001-06-12 Dendreon Corporation Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
NZ522066A (en) 2000-03-30 2004-08-27 Dendreon Corp Compositions and methods for dendritic cell-based immunotherapy
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CN103709250B (zh) 2002-10-17 2016-08-10 根马布股份公司 抗cd20的人单克隆抗体
NZ547279A (en) 2003-10-22 2008-04-30 Keck Graduate Inst Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
EP1861500A2 (en) 2005-03-18 2007-12-05 Innate Pharma Expression vectors and methods for obtaining nk cell specific expression
EP2083857A4 (en) 2006-09-22 2010-03-24 Dana Farber Cancer Res Inc METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
CA2747011C (en) 2008-12-18 2018-06-19 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
WO2012091756A1 (en) 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
SI2760471T1 (sl) 2011-09-30 2017-04-26 Dana-Farber Cancer Institute, Inc. Terapevtski peptidi
CA2862101A1 (en) 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
ES2760023T3 (es) 2013-02-20 2020-05-12 Univ Pennsylvania Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
KR20150130462A (ko) 2013-03-15 2015-11-23 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
BR112016013187A2 (pt) 2013-12-19 2017-09-26 Novartis Ag receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
EP3134514B1 (en) 2014-04-23 2019-09-18 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US20170198054A1 (en) 2014-05-21 2017-07-13 Dana-Farber Cancer Institute Methods for treating cancer with anti bip or anti mica antibodies
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
WO2016064929A1 (en) 2014-10-20 2016-04-28 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
WO2016115559A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CN107709552B (zh) 2015-06-10 2022-05-13 南克维斯特公司 用于治疗癌症的修饰的nk-92细胞
AU2016362597C1 (en) 2015-12-04 2022-05-26 Dana-Farber Cancer Institute, Inc. Vaccination with MICA/B alpha 3 domain for the treatment of cancer
WO2017100709A1 (en) 2015-12-09 2017-06-15 Nant Holdings Ip, Llc Compositions and methods for treatment of her2 positive metastatic breast cancer
AU2017344411A1 (en) 2016-10-19 2019-05-09 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
IL316209A (en) 2017-03-08 2024-12-01 Immunitybio Inc MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
CN117384929A (zh) 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
WO2019004550A1 (ko) 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP2020528885A (ja) 2017-07-19 2020-10-01 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
US20200306302A1 (en) 2017-08-04 2020-10-01 Nantkwest, Inc. Treating and inhibiting leukemia with nk-92 cells
JP2020530294A (ja) 2017-08-09 2020-10-22 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作された細胞を調製するための方法および組成物
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
WO2020028428A2 (en) 2018-07-31 2020-02-06 Pdi Therapeutics, Inc. Anti-mica/b antibodies that block mica/b shedding and methods of use
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
JP7689744B2 (ja) 2019-08-23 2025-06-09 ノースウェスタン ユニバーシティ 抗原特異的ｔ細胞応答を活性化するための材料および方法
CN118414352A (zh) 2021-10-27 2024-07-30 美国株式会社三养生物制药 具有变体fc结构域的抗-mic抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315287A1 (en) 2011-05-31 2012-12-13 University Of Washington Through Its Center For Commercialization Mic-binding antibodies and methods of use thereof
US20160368991A1 (en) * 2013-07-05 2016-12-22 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
WO2020086776A1 (en) * 2018-10-23 2020-04-30 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof

Also Published As

Publication number Publication date
JP2023532852A (ja) 2023-08-01
CA3184940A1 (en) 2022-01-13
KR20230012072A (ko) 2023-01-25
CN116249716A (zh) 2023-06-09
AU2021305084A1 (en) 2023-02-02
US12139539B2 (en) 2024-11-12
KR20230152783A (ko) 2023-11-03
WO2022010847A1 (en) 2022-01-13
TW202216776A (zh) 2022-05-01
EP4178678A1 (en) 2023-05-17
US20230235065A1 (en) 2023-07-27
US20250026837A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
JP2025060941A (ja) Ｃｄ１２３結合性ポリペプチド及びその使用
JP2024164138A (ja) ＣＬＥＣ１２ａ結合性ポリペプチド及びその使用
JP7525510B2 (ja) Ｃｄ３３結合性ポリペプチド及びその使用
US20250026837A1 (en) MIC Antibodies and Binding Agents and Methods of Using the Same
KR102690145B1 (ko) 항ctla-4 항체의 사용
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
TWI867138B (zh) 抗tnfr2抗體及其用途
WO2023010483A1 (en) Anti-human cxcr5 antibody and uses thereof
CA3092434A1 (en) Compositions of a novel anti-human ceacam6 antibody and uses thereof
JP2025538606A (ja) 抗ｃｃｒ８抗体及びその使用
CN107148474A (zh) 抗人Gas6单克隆抗体
CN117279954A (zh) 抗人cxcr5抗体及其用途
HK40087490A (zh) Mic抗体和结合剂及其使用方法
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
EA046221B1 (ru) Cd33-связывающие полипептиды и их применение
EA046257B1 (ru) Clec12a-связывающие полипептиды и их применение

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601